Characteristics of patients infused with prophylactic virus-specific T cells
| Characteristic . | Infused patients (n = 23), n (%) . |
|---|---|
| Gender | |
| Male | 11 (47.8) |
| Female | 12 (52.2) |
| Race/ethnicity | |
| Hispanic | 2 (8.7) |
| Black or African American | 1 (4.3) |
| White | 13 (56.5) |
| Other | 7 (30.4) |
| Median age at infusion, y (range) | 10.3 (0.7-22.9) |
| Transplantation type | |
| Matched unrelated donor | 13 (56.5) |
| Matched related donor | 7 (30.4) |
| Mismatched unrelated donor | 2 (8.7) |
| Haploidentical donor | 1 (4.3) |
| Stem cell source | |
| Bone marrow | 11 (47.8) |
| Peripheral blood | 12 (52.2) |
| Conditioning regimen | |
| Myeloablative | 16 (69.6) |
| Reduced intensity | 7 (30.4) |
| Reason for transplantation | |
| Malignancy | 12 (52.2) |
| Immunodeficiency | 2 (8.7 |
| Nonmalignant hematology | 2 (8.7) |
| Bone marrow failure syndrome | 7 (30.4) |
| Serotherapy received during conditioning | |
| Alemtuzuma | 5 (21.7) |
| ATG | 6 (26.1) |
| GVHD prophylaxis | |
| Calcineurin inhibitor-containing regimen | 14 (60.9) |
| Ex vivo T-cell depletion | 9 (39.1) |
| Abatacept | 8 (34.7) |
| Characteristic . | Infused patients (n = 23), n (%) . |
|---|---|
| Gender | |
| Male | 11 (47.8) |
| Female | 12 (52.2) |
| Race/ethnicity | |
| Hispanic | 2 (8.7) |
| Black or African American | 1 (4.3) |
| White | 13 (56.5) |
| Other | 7 (30.4) |
| Median age at infusion, y (range) | 10.3 (0.7-22.9) |
| Transplantation type | |
| Matched unrelated donor | 13 (56.5) |
| Matched related donor | 7 (30.4) |
| Mismatched unrelated donor | 2 (8.7) |
| Haploidentical donor | 1 (4.3) |
| Stem cell source | |
| Bone marrow | 11 (47.8) |
| Peripheral blood | 12 (52.2) |
| Conditioning regimen | |
| Myeloablative | 16 (69.6) |
| Reduced intensity | 7 (30.4) |
| Reason for transplantation | |
| Malignancy | 12 (52.2) |
| Immunodeficiency | 2 (8.7 |
| Nonmalignant hematology | 2 (8.7) |
| Bone marrow failure syndrome | 7 (30.4) |
| Serotherapy received during conditioning | |
| Alemtuzuma | 5 (21.7) |
| ATG | 6 (26.1) |
| GVHD prophylaxis | |
| Calcineurin inhibitor-containing regimen | 14 (60.9) |
| Ex vivo T-cell depletion | 9 (39.1) |
| Abatacept | 8 (34.7) |